Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells + IL-2 + Vactosertib in Advanced Solid Tumors and Hematologic Malignancies
NCT05400122Phase 1Suspended
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Natural Killer Cells in colorectal cancer (CRC), gastric cancer (GC), esophageal cancer and 1 more. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days and Persistence of donor NK cells at 7 days. Started Sep 2022; status: suspended.
02
Drugs
Natural Killer Cells
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)esophageal cancerhematologic malignancy
Beyond the preview
Go deeper on NCT05400122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400122.